<DOC>
	<DOCNO>NCT01195454</DOCNO>
	<brief_summary>Primary Objective : - To assess total metabolic effect ratios new insulin glargine formulation versus Lantus® Secondary Objectives : - To assess exposure ratio new insulin glargine formulation versus Lantus® - To compare duration action new insulin glargine formulation versus Lantus® - To explore dose response dose exposure relationship new insulin glargine formulation - To assess safety tolerability new insulin glargine formulation</brief_summary>
	<brief_title>Euglycemic Clamp Dose-response Study Comparing New Insulin Glargine Formulation With Lantus®</brief_title>
	<detailed_description>The study period one patient one month average last 11 week broken follow : - Screening : 3 28 day - Treatment period : 1 4 day : 2 day ( 1 overnight stay ) - Washout period : 5 18 day ( preferentially 7 day consecutive dosings ) - End study : 1 day last dosing</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Male female subject diabetes mellitus type 1 one year , Total insulin dose &lt; 1.2 U/kg/day , Glycohemoglobin ( HbA1c ) ≤ 9.0 % , Fasting negative serum Cpeptide ( &lt; 0.3 nmol/L ) , Stable insulin regimen least 2 month prior study , Normal find medical history physical examination ( cardiovascular system , chest lung , thyroid , abdomen , nervous system , skin mucosa , musculoskeletal system ) , vital sign , electrocardiogram ( ECG ) safety lab , Women childbearing potential negative pregnancy test use highly effective contraceptive method woman confirm postmenopausal status . Exclusion criterion : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart diabetes mellitus type 1 ) , hematological , neurological , psychiatric , systemic ( affect body whole ) , ocular , gynecologic ( female ) , infectious disease ; acute infectious disease sign acute illness , More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month , Frequent severe headache / migraine , recurrent nausea / vomiting ( twice month ) , Symptomatic hypotension ( whatever decrease blood pressure ) , asymptomatic postural hypotension define decrease SBP equal great 20 mmHg within three minute change supine stand position , Presence history drug allergy clinically significant allergic disease , Likelihood require treatment study period drug permit clinical study protocol , Pregnant breast feeding woman , Any medication ( include St John 's Wort ) within 14 day inclusion , within 5 time elimination halflife pharmacodynamic halflife drug , whichever long regular use medication insulin last month study start exception thyroid hormone , lipidlowering antihypertensive drug , , female , exception hormonal contraception menopausal hormone replacement therapy ; vaccination within last 28 day , Positive reaction follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis B core antibody ( antiHBc Ab ) compound possible immune activity , antihepatitis C virus ( antiHCV2 ) antibody , antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 anti HIV2 Ab ) , Known hypersensitivity insulin glargine excipients , Any history presence deep leg vein thrombosis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>